Sio Gene Therapies Beheer
Beheer criteriumcontroles 0/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
David Nassif
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 4.6yrs |
| Eigendom CEO | 0.06% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | geen gegevens |
Recente managementupdates
Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?
Mar 04
Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?
Nov 19Recent updates
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?
Oct 19Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Jun 27My Favorite Stock For 2022: Sio Gene Therapies
Dec 27Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure
Oct 25We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely
Sep 28Sio Gene Therapies EPS beats by $0.12
Jun 09Sio Gene Therapies: Gene Therapies For Neurodegeneration
May 28We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully
May 07Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?
Mar 04Sio Gene Therapies secures $11.6M from sale of Arvelle Therapeutics
Feb 04What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?
Jan 28Sio Gene Therapies to sell Arvelle stake to Angelini Pharma
Jan 04Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Dec 24Sio Gene Therapies soars 45% on positive AXO-AAV-GM1 data in nerve cell disorder
Dec 16Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?
Nov 19Axovant on go with pivotal study of gene therapy for rare inherited lipid disorders
Nov 09Axovant sees delayed enrollment in Parkinson’s study with gene therapy
Oct 29Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2022 | n/a | n/a | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$50m |
| Jun 30 2022 | n/a | n/a | -US$68m |
| Mar 31 2022 | US$2m | US$454k | -US$72m |
| Dec 31 2021 | n/a | n/a | -US$62m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | US$1m | US$414k | -US$32m |
| Dec 31 2020 | n/a | n/a | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$49m |
| Jun 30 2020 | n/a | n/a | -US$53m |
| Mar 31 2020 | US$2m | US$300k | -US$73m |
Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van David redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.
Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.
CEO
David Nassif (69 yo)
4.6yrs
Tenure
US$1,617,173
Compensatie
Mr. David W. Nassif, J.D., serves as Chief Executive Officer of Sio Gene Therapies Inc. since May 2022 and also serves as its General Counsel since July 01, 2019 and serves as its Chief Financial Officer....